Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$2.85 -2.4%	$3.26	$2.56 ▼ $7.73	$370.80M	0.18	5.67 million shs	2.28 million shs
BMY Bristol Myers Squibb	$57.04 +0.5%	$58.63	$42.52 ▼ $62.89	$116.40B	0.26	10.19 million shs	10.82 million shs
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	N/A
NBIX Neurocrine Biosciences	$158.42 -0.4%	$134.05	$117.59 ▼ $162.39	$15.93B	0.34	1.31 million shs	1.31 million shs
RYZB RayzeBio	$62.49	$62.47	$17.95 ▼ $62.51	$3.74B	N/A	553,592 shs	N/A
TRML Tourmaline Bio	$47.98	$47.95	$13.27 ▼ $48.27	$1.23B	2.27	592,710 shs	N/A
XENE Xenon Pharmaceuticals	$54.39 -2.9%	$56.07	$28.19 ▼ $63.95	$5.26B	0.65	955,064 shs	610,337 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	-7.77%	-18.80%	-37.09%	-50.00%
BMY Bristol Myers Squibb	0.00%	+1.68%	-3.16%	-5.94%	+29.46%
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NBIX Neurocrine Biosciences	0.00%	+4.05%	+23.37%	+27.63%	+33.37%
RYZB RayzeBio	0.00%	0.00%	0.00%	0.00%	0.00%
TRML Tourmaline Bio	0.00%	0.00%	0.00%	0.00%	+209.55%
XENE Xenon Pharmaceuticals	0.00%	-3.63%	-6.91%	+31.12%	+82.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$2.85 -2.4%	$3.26	$2.56 ▼ $7.73	$370.80M	0.18	5.67 million shs	2.28 million shs
BMY Bristol Myers Squibb	$57.04 +0.5%	$58.63	$42.52 ▼ $62.89	$116.40B	0.26	10.19 million shs	10.82 million shs
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	N/A
NBIX Neurocrine Biosciences	$158.42 -0.4%	$134.05	$117.59 ▼ $162.39	$15.93B	0.34	1.31 million shs	1.31 million shs
RYZB RayzeBio	$62.49	$62.47	$17.95 ▼ $62.51	$3.74B	N/A	553,592 shs	N/A
TRML Tourmaline Bio	$47.98	$47.95	$13.27 ▼ $48.27	$1.23B	2.27	592,710 shs	N/A
XENE Xenon Pharmaceuticals	$54.39 -2.9%	$56.07	$28.19 ▼ $63.95	$5.26B	0.65	955,064 shs	610,337 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	-7.77%	-18.80%	-37.09%	-50.00%
BMY Bristol Myers Squibb	0.00%	+1.68%	-3.16%	-5.94%	+29.46%
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NBIX Neurocrine Biosciences	0.00%	+4.05%	+23.37%	+27.63%	+33.37%
RYZB RayzeBio	0.00%	0.00%	0.00%	0.00%	0.00%
TRML Tourmaline Bio	0.00%	0.00%	0.00%	0.00%	+209.55%
XENE Xenon Pharmaceuticals	0.00%	-3.63%	-6.91%	+31.12%	+82.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.50	Moderate Buy	$17.50	514.04% Upside
BMY Bristol Myers Squibb	2.37	Hold	$61.31	7.49% Upside
KRTX Karuna Therapeutics	0.00	N/A	N/A	N/A
NBIX Neurocrine Biosciences	2.82	Moderate Buy	$184.15	16.24% Upside
RYZB RayzeBio	0.00	N/A	N/A	N/A
TRML Tourmaline Bio	2.00	Hold	$47.94	-0.07% Downside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.07	41.69% Upside

Current Analyst Ratings Breakdown

Latest BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2026	ALT Altimmune	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$14.00 ➝ $11.00
5/12/2026	XENE Xenon Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$77.00 ➝ $80.00
5/10/2026	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$69.00
5/8/2026	NBIX Neurocrine Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$177.00 ➝ $185.00
5/8/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$80.00 ➝ $82.00
5/8/2026	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$80.00 ➝ $78.00
5/7/2026	NBIX Neurocrine Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $155.00
5/6/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$185.00 ➝ $191.00
5/6/2026	NBIX Neurocrine Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$242.00 ➝ $246.00
5/6/2026	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$176.00 ➝ $180.00
5/6/2026	NBIX Neurocrine Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$175.00

(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$36K	10,299.98	N/A	N/A	$2.18 per share	1.31
BMY Bristol Myers Squibb	$48.19B	2.42	$8.14 per share	7.01	$9.84 per share	5.80
KRTX Karuna Therapeutics	$654K	19,239.07	N/A	N/A	$33.24 per share	9.92
NBIX Neurocrine Biosciences	$2.86B	5.57	$5.01 per share	31.61	$33.89 per share	4.67
RYZB RayzeBio	N/A	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	$13.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$88.09M	-$0.93	N/A	N/A	N/A	-214,860.98%	-42.57%	-35.57%	N/A
BMY Bristol Myers Squibb	$7.05B	$3.56	16.02	9.40	0.16	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
KRTX Karuna Therapeutics	-$433.68M	-$11.72	N/A	N/A	N/A	N/A	-31.63%	-30.38%	N/A
NBIX Neurocrine Biosciences	$478.60M	$6.49	24.41	16.82	1.19	21.55%	19.79%	13.82%	7/29/2026 (Estimated)
RYZB RayzeBio	-$68.60M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	-$73.21M	-$3.43	N/A	N/A	N/A	N/A	-30.50%	-29.63%	N/A
XENE Xenon Pharmaceuticals	-$345.91M	-$4.70	N/A	N/A	N/A	N/A	-49.23%	-46.42%	N/A

Latest BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q1 2026	ALT Altimmune	-$0.25	-$0.18	+$0.07	-$0.18	$0.00 million	N/A
5/7/2026	Q1 2026	XENE Xenon Pharmaceuticals	-$1.17	-$1.17	N/A	-$1.17	$1.36 million	N/A
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
3/5/2026	Q4 2025	ALT Altimmune	-$0.25	-$0.2719	-$0.0219	-$0.27	$0.00 million	$0.03 million
2/26/2026	Q4 2025	XENE Xenon Pharmaceuticals	-$1.20	-$1.31	-$0.11	-$1.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	$2.52	4.42%	+1.61%	70.79%	17 Years
KRTX Karuna Therapeutics	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
RYZB RayzeBio	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.12	29.56	18.55
BMY Bristol Myers Squibb	2.10	1.42	1.28
KRTX Karuna Therapeutics	N/A	19.31	19.31
NBIX Neurocrine Biosciences	N/A	2.93	2.85
RYZB RayzeBio	N/A	31.85	31.85
TRML Tourmaline Bio	N/A	24.68	24.68
XENE Xenon Pharmaceuticals	N/A	27.79	27.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
BMY Bristol Myers Squibb	76.41%
KRTX Karuna Therapeutics	N/A
NBIX Neurocrine Biosciences	92.59%
RYZB RayzeBio	N/A
TRML Tourmaline Bio	91.89%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	1.60%
BMY Bristol Myers Squibb	0.05%
KRTX Karuna Therapeutics	13.20%
NBIX Neurocrine Biosciences	4.60%
RYZB RayzeBio	N/A
TRML Tourmaline Bio	13.00%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	130.11 million	128.02 million	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
KRTX Karuna Therapeutics	339	38.15 million	33.16 million	Optionable
NBIX Neurocrine Biosciences	2,000	100.55 million	95.93 million	Optionable
RYZB RayzeBio	88	59.92 million	N/A	No Data
TRML Tourmaline Bio	44	25.69 million	22.35 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	92.73 million	Optionable

BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 14 at 5:02 PM | seekingalpha.com

Stock Traders Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

May 14 at 4:51 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00 at JPMorgan Chase & Co.

May 12, 2026 | marketbeat.com

Equities Analysts Set Expectations for XENE Q2 Earnings

May 12, 2026 | marketbeat.com

State of New Jersey Common Pension Fund D Sells 35,973 Shares of Xenon Pharmaceuticals Inc. $XENE

May 12, 2026 | marketbeat.com

A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase 3 X TOLE2 Success And Extended Cash Runway

May 11, 2026 | finance.yahoo.com

Did Positive X-TOLE2 Data and a Major Cash Raise Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?

May 11, 2026 | finance.yahoo.com

Nan Fung Trinity HK Ltd. Has $10.17 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

May 10, 2026 | marketbeat.com

Xenon Pharmaceuticals Q1 Earnings Call Highlights

May 9, 2026 | marketbeat.com

Xenon Highlights Positive Phase 3 Azetukalner Seizure Data

May 8, 2026 | theglobeandmail.com

Xenon Q1 earnings match estimates, pipeline development in focus

May 8, 2026 | msn.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

May 8, 2026 | marketbeat.com

Needham & Company LLC Cuts Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $78.00

May 8, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

Xenon Pharmaceuticals: Q1 Earnings Snapshot

May 7, 2026 | finance.yahoo.com

Xenon (XENE) Q1 2026 Earnings Transcript

May 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results

May 7, 2026 | marketbeat.com

Xenon Reports Q1 2026 Financial Results and Provides Business Update

May 7, 2026 | globenewswire.com

Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

May 7, 2026 | globenewswire.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages

May 6, 2026 | marketbeat.com

Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

May 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Company Descriptions

Altimmune NASDAQ:ALT

$2.85 -0.07 (-2.40%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$2.87 +0.02 (+0.70%)

As of 05/15/2026 07:54 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Bristol Myers Squibb NYSE:BMY

$57.04 +0.27 (+0.47%)

Closing price 05/15/2026 03:59 PM Eastern

Extended Trading

$56.76 -0.27 (-0.48%)

As of 05/15/2026 07:34 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Neurocrine Biosciences NASDAQ:NBIX

$158.42 -0.63 (-0.40%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$161.00 +2.58 (+1.63%)

As of 05/15/2026 07:49 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

RayzeBio NASDAQ:RYZB

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Tourmaline Bio NASDAQ:TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Xenon Pharmaceuticals NASDAQ:XENE

$54.39 -1.61 (-2.88%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$53.62 -0.77 (-1.41%)

As of 05/15/2026 06:04 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Earnings

Compare Dividends

Latest BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BMY, NBIX, TRML, XENE, ALT, KRTX, and RYZB Company Descriptions

Altimmune NASDAQ:ALT

Bristol Myers Squibb NYSE:BMY

Karuna Therapeutics NASDAQ:KRTX

Neurocrine Biosciences NASDAQ:NBIX

RayzeBio NASDAQ:RYZB

Tourmaline Bio NASDAQ:TRML

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools